This inventor holds 6 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bioscience and Biotechnology, Enzychem Co., Ltd.. Active years: 2011-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Taejon, KR (2011)
- Daejeon, KR (2017 - 2021)
Company Filing History:
5 out of 22 
3 out of 334 
1 out of 1 Years Active: 2011-2021
Title: Innovations of Tae-Suk Lee in Asthma and Pulmonary Disease Treatments
Introduction
Tae-Suk Lee is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of asthma and chronic obstructive pulmonary diseases (COPD). With a total of six patents to his name, his work focuses on innovative compositions that aim to improve health outcomes for patients suffering from these conditions.
Latest Patents
One of Tae-Suk Lee's latest patents is a composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma. This invention relates to a pharmaceutical composition that not only addresses asthma but also serves as a functional health food composition. The monoacetyldiacylglycerol compound has been shown to inhibit the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells. It reduces airway hypersensitivity in asthma-induced animal models and inhibits the infiltration of inflammatory cells into the bronchial tube. Furthermore, this compound effectively inhibits the generation of IgE in serum and bronchoalveolar lavage fluid, demonstrating a superior therapeutic effect without toxicity.
Another significant patent by Tae-Suk Lee involves a composition containing a monoacetyldiacylglycerol compound for preventing or treating chronic obstructive pulmonary disease. Similar to his asthma treatment, this invention also focuses on a pharmaceutical composition that can alleviate COPD symptoms. The monoacetyldiacylglycerol compound inhibits IL-4 expression in EL-4 cells and inflammatory cell infiltration in the bronchial tube. It also shows an excellent effect in inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thus overcoming the side effects of currently used therapeutic agents for COPD.
Career Highlights
Tae-Suk Lee has worked with prominent organizations such as Enzychem Lifesciences Corporation and the Korea Research Institute of Bioscience and Biotechnology. His experience in these institutions has contributed to his innovative research and development in the pharmaceutical field.
Collaborations
Some of his notable coworkers include Sei-Ryang Oh and Kyung Seop Ahn, who have collaborated with him on various projects related to his patents and research.
Conclusion
Tae-Suk Lee's contributions to the treatment of asthma and chronic obstructive pulmonary diseases through
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile